PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double‐blind, placebo‐controlled study

@article{Dinsmore2009PSD502IE,
  title={PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double‐blind, placebo‐controlled study},
  author={W. W. Dinsmore and Michael Grant Wyllie},
  journal={BJU International},
  year={2009},
  volume={103}
}
To determine the effect of PSD502 applied topically 5 min before intercourse on the Index of Premature Ejaculation (IPE) and intravaginal ejaculatory latency time (IELT) of men with lifelong premature ejaculation (PE) defined according to the International Society of Sexual Medicine (ISSM) definition; secondary objectives were to evaluate the safety and tolerability of PSD502 in patients with PE, and their sexual partners. 

Paper Mentions

Observational Clinical Trial
An observational study on the effect of new classification for premature ejaculation.  
ConditionsPremature Ejaculation
Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study.
TLDR
In this study, PSD502 applied topically to the glans penis 5 minutes before intercourse showed significantly improved ejaculatory latency, ejaculatory control, sexual satisfaction and distress and was shown to be well tolerated by patients and partners. Expand
Sexual dysfunction: Topical spray treatment for premature ejaculation
TLDR
Assessments revealed notably greater improvements in perceived control, personal distress, and satisfaction with sexual intercourse for patients and partners in the PsD502 group compared with those in the placebo group. Expand
Sexual dysfunction: Anesthetic spray improves premature ejaculation
TLDR
A metered-dose aerosol spray containing lidocaine and prilocaine showed a 6.3-fold increase in intravaginal ejaculatory latency times, improved all patient-reported outcomes and had no serious adverse effects. Expand
Premature ejaculation: treatment update
TLDR
An overview of current accepted treatments and emerging agents for the use in PE is provided and a greater emphasis placed on researching novel treatments and exploring the on-demand use of current preparations is placed. Expand
Evolving therapeutic strategies for premature ejaculation: The search for on-demand treatment - topical versus systemic.
  • A. Morales
  • Medicine
  • Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • 2012
TLDR
Evidence demonstrated that PSD502, dapoxetine and other SSRIs all significantly improve the symptoms of PE, and systemic use of SSRIS presents risks associated with the known pharmacology of this class. Expand
Fortacin™ Spray for the Treatment of Premature Ejaculation
TLDR
The metered-dose spray delivery system allows the desensitizing agents to be deposited in a dose-controlled, concentrated film onto the glans penis consequently reducing its sensitivity, translating into a delaying of the ejaculatory latency time without adversely affecting the sensation of ejaculation and orgasmic pleasure. Expand
New Concepts in the Diagnosis and Treatment of Premature Ejaculation
TLDR
Emerging medications and the ability to tailor treatments based on genetic information likely will change the paradigm of this disorder and how it will be treated by clinicians. Expand
Medical therapy for premature ejaculation
TLDR
Dapoxetine, which is a on-demand SSRI, is the only licensed drug for the treatment of PE, increasing IELT by a factor of 2.5 to 3 with limited and tolerable side effects. Expand
Lidocaine/prilocaine spray for premature ejaculation
  • Dtb Cmecpd
  • Medicine
  • Drug and Therapeutics Bulletin
  • 2017
TLDR
The evidence for lidocaine/prilocaine spray and whether it has a role in the treatment of premature ejaculation is considered. Expand
Content Validity of the Premature Ejaculation Profile, Original and Per-Event Formats, in Men with Lifelong Premature Ejaculation.
TLDR
Both the original and per-event PEP versions were shown to have strong content validity and be acceptable for use in men with lifelong PE and addressed gaps in previously published research on the development and validation of the PEP. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 29 REFERENCES
Premature ejaculation: an observational study of men and their partners.
TLDR
Shorter IELT was significantly associated with reduced ejaculatory control and sexual satisfaction and increased distress and interpersonal difficulty, indicating the need for additional PRO measures to characterize PE. Expand
Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine
To assess the utility of perceived control over ejaculation (‘control’) in the evaluation of treatment benefit in men with premature ejaculation (PE), and to compare effects associated with aExpand
Topical lidocaine–prilocaine spray for the treatment of premature ejaculation: a proof of concept study
TLDR
Topical LP spray, applied to the glans penis 15 min before intercourse, prolongs ejaculation time significantly and improves sexual satisfaction in both men with PE and their partners. Expand
A multinational population survey of intravaginal ejaculation latency time.
TLDR
The distribution of the Intravaginal ejaculation latency time (IELT) in all the five countries was positively skewed, with a median IELT of 5.4 minutes but with differences between countries, which was significantly different from each of the other countries. Expand
‘Up and coming’ treatments for premature ejaculation: progress towards an approved therapy
TLDR
A number of emerging therapies in various stages of development that show potential for use in the treatment of PE are reviewed, which may prove to offer the most favourable risk: benefit profile as well as the flexibility to adapt to differing frequencies of sexual activity. Expand
Self-reported premature ejaculation and aspects of sexual functioning and satisfaction.
TLDR
PE was a common problem, was characterized by a lack of ejaculatory control, and was associated with significant effects on sexual functioning and satisfaction, and additional research on the sensitivity and specificity of these self-report questions should be pursued. Expand
Safety and Efficacy of Dapoxetine in the Treatment of Premature Ejaculation: A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Study
TLDR
Dapoxetine has moderately better results in terms of IELT and intercourse satisfaction vs placebo without long-term benefit for the patient after it is withdrawn, and further studies are necessary to draw final conclusions on the efficacy of this drug in PE. Expand
On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomized, double-blind fixed-dose study with stopwatch assessment.
TLDR
On-demand treatment with 25 mg clomipramine led to a clinical relevant ejaculation delay in men with lifelong premature ejaculation with an IELT of less than 1 minute, and in contrast, 20 mg paroxetine had no clinical relevant genitalia delay. Expand
Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials
TLDR
On-demand dapoxetine is an effective and generally well tolerated treatment for men with moderate-to-severe premature ejaculation. Expand
TEMPE: Topical Eutectic-Like Mixture for Premature Ejaculation
TLDR
The authors evaluate here the progress that has been made towards the reformulation of these local anaesthetic agents into a unique eutectic-like formulation for use as a desensitising agent in the treatment of premature ejaculation, as well as examining other potential uses for the spray. Expand
...
1
2
3
...